This Core recruits, enrolls and evaluates all subjects entered into the studies of the program project. It uses established clinical protocols at entry and at all assessments to obtain relevant clinical, neurological, and cognitive data to carefully characterize each subject, including for dementia diagnosis and staging. Core data are used by all Cores and projects to explore the correlates of very mild dementia of the Alzheimer type (DAT) in comparison with healthy brain aging. The Core recruits and maintains adequate samples to supply needed subjects for all projects and other cores. In addition to maintaining the longitudinal sample of subjects 65+years (required in all projects) the Core will recruit a sample of subjects at high risk for dementia (Adult Children Study) ages 45-74 to explore antecendents of Alzheimer disease in Project 2 (Novel Biomarkers to Predict Alzheimer's disease), Project 3 (Attention Profiles in Healthy Aging Early Stage DAT)and 4 (Predicting Cognitive Decline in Healthy Elders). For Project 1 (Dementia Assessment in the Community) a shortened dementia assessment is to be tested in the community and this Core will assess subjects using our established clinical protocols to validate the brief instrument. Through its successful voluntary autopsy program, it supplies Core C: Neuropathology with autopsy material and therefore the neuropatholgic diagnoses for the Projects. Core A: Clinical works closely with Core B: Psychometrics to integrate the clinical and psychometric assessments for all subjects and with CoreD: Biostatistics to ensure appropriate data management. The Core supports Core E: Administrative in promoting scientific interactions among all investigators to accomplish the aims of the program project as a whole.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG003991-25
Application #
7570051
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2008-01-01
Budget End
2008-12-31
Support Year
25
Fiscal Year
2008
Total Cost
$507,516
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Maxwell, Taylor J; Corcoran, Chris; Del-Aguila, Jorge L et al. (2018) Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels. Alzheimers Res Ther 10:86
Cruchaga, Carlos; Del-Aguila, Jorge L; Saef, Benjamin et al. (2018) Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement 14:205-214
Brainstorm Consortium (see original citation for additional authors) (2018) Analysis of shared heritability in common disorders of the brain. Science 360:
Kinnunen, Kirsi M; Cash, David M; Poole, Teresa et al. (2018) Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. Alzheimers Dement 14:43-53
Ibanez, Laura; Dube, Umber; Davis, Albert A et al. (2018) Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. Front Neurosci 12:230
Schultz, Stephanie A; Gordon, Brian A; Mishra, Shruti et al. (2018) Widespread distribution of tauopathy in preclinical Alzheimer's disease. Neurobiol Aging 72:177-185
Broce, Iris; Karch, Celeste M; Wen, Natalie et al. (2018) Correction: Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Med 15:e1002504
Javaherian, Kavon; Newman, Brianne M; Weng, Hua et al. (2018) Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease. Alzheimer Dis Assoc Disord :
Jansen, Willemijn J; Ossenkoppele, Rik; Tijms, Betty M et al. (2018) Association of Cerebral Amyloid-? Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry 75:84-95
Liao, Fan; Li, Aimin; Xiong, Monica et al. (2018) Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest 128:2144-2155

Showing the most recent 10 out of 911 publications